Charting New Waters: Polar's Treatment Evolution into March

As we navigate through February and into the early days of March, the journey with Polar, our beloved Siberian Husky battling a malignant perianal tumor, takes a new turn. Here's what's on the horizon:

Exploring New Synergies:

Ivermectin Introduction: We're at a pivotal moment where we're contemplating the addition of ivermectin to Polar's treatment plan. Inspired by the work of Dr. William Makis and the potential synergy with fenbendazole, we're cautiously optimistic. The plan is to integrate ivermectin at a low, safe dose, with the possibility of adjusting based on Polar's response. This step could unlock a new layer of treatment efficacy we haven't yet explored.

Health Diagnostics:

Gene and Liver Tests: Before any new treatment can commence, we're gearing up for essential tests. The gene test for the MDR1 mutation will determine if ivermectin is a viable option for Polar, avoiding potential adverse reactions. Simultaneously, we'll assess his liver function to ensure it can handle the current regimen and any new additions.

Strategic Adjustments:

Fenbendazole Frequency: If our tests are favorable and ivermectin at a starting dose shows no significant benefit, the logical approach would be to first incrementally increase the ivermectin dose. Given the lack of comprehensive veterinary data on higher doses of ivermectin for cancer, this step must be taken with extreme caution, monitoring for any signs of toxicity. Only if this adjustment also yields no notable result would we then consider increasing the frequency of fenbendazole administration. This adjustment could move from our current 3-4 days a week to a more aggressive schedule of 5-6 days, following insights from Dr. Makis's protocols, always under veterinary supervision. Although Dr. Makis typically starts human patients with fenbendazole 6 days a week, our approach with Polar might differ by first testing the waters with ivermectin. Before jumping to the highest frequency, we might consider a slight increase from 3x to 4x per week, finding a middle ground between the original press-pulse schedule from '97 and Dr. Makis's more aggressive approach, if progress remains elusive.

Community Engagement:

Ivy Inu Launch: In parallel to Polar's health journey, we're planning the launch of Ivy Inu, Polar's 'daughter' in the crypto world. Ivy's launch isn't just about expanding our crypto narrative; it's a concerted effort to fund and support Polar's treatment further. Ivy could become a beacon of hope, potentially securing funds for expert consultations, research, or even new treatments. We're looking at a launch window of 2-4 weeks, ensuring we weave this narrative with care and community input.

A New Perspective on Progress:

Beyond the Tumor: We've learned that progress isn't always about tumor size reduction but can also be about stabilization, quality of life, and managing symptoms. This broader view helps us appreciate the small victories in Polar's health journey, even if the tumor's response remains elusive.

Looking Ahead:

Consultations with Experts: We're reaching out to veterinarians and doctors known for their work in alternative cancer treatments, seeking advice or potential consultations. This might include those like Dr. Demian Dressler, known for his holistic approaches, or others who might offer a fresh perspective on Polar's case.
Community Feedback: As always, your thoughts and experiences are invaluable. We're considering how we can engage more on this journey, perhaps through live sessions, Q&A, or detailed updates where you can ask questions directly related to Polar's treatment evolution.

Conclusion:

As we move into March, every step we take is with the hope of not just managing but potentially overcoming this challenge with Polar. Each decision, each test, each community support gesture is a part of this intricate journey. Your involvement, whether through support for Ivy Inu or sharing knowledge, is what keeps this story moving forward. Together, we're not just treating a dog; we're pioneering a path where technology, community, and healing converge.

Note: All treatment decisions for Polar are made in consultation with veterinary professionals. This post aims to document our journey and gather insights, not to provide medical advice.